Prophylaxis Vaccine Antibodies Ebola

Inclusion Criteria

• •Have had, within the previous 72 hours, a high-risk contact with an Ebola patient confirmed by RT-PCR;
• •Be 18 years of age or older at the time of inclusion;
• •Have no symptoms of EVD;
• •Give consent to participate in the efficacy trial;
• •Agree not to participate in any other therapeutic or vaccine study until the end of the trial follow-up.
• •The criteria for non-inclusion in the efficacy trial are:
• •Have a history of EVD (self-report);
• •Have been vaccinated with ERVEBO prior to the start of the study;
• •Have participated in another therapeutic or vaccine study within 15 days prior to inclusion.
• •High Risk Arm:
• •Be included in the efficacy trial;
• •Be available for extended follow-up as specified in the protocol;
• •Specifically consent to the immunology ancillary study.
• •Control arm:
• •Be 18 years of age or older at the time of inclusion;
• •Have no symptoms of EVD;
• •Eligible for ERVEBO vaccination according to national program criteria;
• •Be available for extended follow-up as specified in the protocol;
• •Consent specifically for the ancillary immunology study.
• •The criteria for non-inclusion in the immunologic ancillary study are:
• •HIV positive;
• •Pregnant women.